authors proposed an intriguing mechanism for PML regulation that involves the ubiquitin-proteasome degradation pathway.
Treatment with a proteasome inhibitor restored PML protein expression in cell lines that expressed PML mRNA but not PML protein. This result is not surprising because post-translational modification by Sumo-1, the ubiquitin-like modifier, affects PML nuclear bodies (3) . It is interesting to note that previous gene profiling studies revealed that the E1-like ubiquitinactivating enzyme UBE1L can be induced by all-trans-retinoic acid treatment of APL cells (23) . UBE1L is a retinoic acid target gene that promotes apoptosis and PML-RAR␣ degradation (24) . Activation of the ubiquitin-proteasome degradation pathway also occurs during retinoid-induced tumor cell differentiation and chemoprevention (4) . Cell cycle regulators were identified as molecular targets for these pharmacologic effects. PML protein may be directly affected by UBE1L or regulators of the proteasome degradation pathway, and future work should explore this possibility.
Additional studies are needed to establish whether a proteasome-dependent mechanism was predominantly responsible for repression of the PML protein in the cancers studied by Gurrieri et al. (1) . Nevertheless, there are therapeutic implications to finding that regulation of PML was proteasomedependent. Proteasome inhibition has clinical activity (25) . Clinical use of a proteasome inhibitor might restore PML expression and thereby confer its activity as a tumor suppressor. Although the currently available proteasome inhibitors do not target PML specifically, clinical treatment with these agents would address whether PML expression can be restored in malignant tumors.
The data in Gurrieri et al. (1) are consistent with an important role for PML repression in regulating the growth of cancers in patients. PML repression occurred early during prostate carcinogenesis, even at the transition from prostatic intraepithelial neoplasia to invasive prostate carcinoma. Statistically significant associations were also observed for PML repression in breast and central nervous system cancers. These data would have been strengthened by inclusion of paired normal and malignant tumor specimens from the same patients. Yet, these findings do suggest a regulatory role for PML in the growth of certain tumors. Future work should establish whether restoration of PML expression has therapeutic benefits. It is also important to consider other post-transcriptional mechanisms for PML silencing.
It is not unexpected to find that PML might have a role in other cancers in addition to APL. Prior work revealed that other translocation partners have regulatory roles beyond the hematopoietic malignancy in which they were first found, as in rearrangements of myc in Burkitt's lymphoma (26) . A similar case could be made for the retinoblastoma gene product, Rb. This tumor suppressor was first identified in a childhood cancer, but it has a critical role in regulating growth of other malignancies (27) . The article by Gurrieri et al. has prioritized those tumors in which PML might function in carcinogenesis by determining clinical settings in which PML expression was frequently lost or repressed.
The study by Gurrieri et al.
(1) underscores how useful tissue microarrays can be in uncovering key steps in carcinogenesis. This is an example of merging hypothesis-driven and hypothesis-generating strategies to uncover a potential molecular target for cancer therapy or chemoprevention. Because PML repression is frequent in many different malignancies, it is now important to determine precisely how repression occurs and what its biologic impact is. Whether PML repression can be pharmacologically overcome should be studied. A translational research approach is needed to address these points. Preliminary data have implicated the ubiquitin-proteasome pathway in this PML regulation. However, it is important to explore which post-transcriptional or post-translational mechanisms are engaged to alter PML expression. Different mechanisms could cooperate to affect PML expression.
In summary, the article by Gurrieri et al.
(1) highlights an emerging approach in molecular oncology. Hypothesis-driven and hypothesis-generating strategies are not mutually exclusive. Merging these approaches will hasten the process of translating discoveries from the bench to the bedside and back again. We should apply genomic, proteomic, and tissue-based microarray techniques to this purpose.
